Shinonogi & Co., Ltd is developing S-004992 in collaboration with its originator C&O Pharmaceutical Technology (Holdings) Limited of China, a Shionogi’s subsidiary. Now in GLP studies, S-004992 may enter clinical studies in April 2020.
Compound
S-004992
Shionogi & Co., Ltd
Description
Related Links
Developer Associations